Bacteriostatic Water · Research brief

How to Inject Tesofensine Subq — Protocol & Technique

Real Peptides Research TeamEditorial

Updated July 6, 20269 min read

49 WORDS

Short answer

Research from peptide stability studies shows that subcutaneous injection technique affects tesofensine absorption by 20–35%. Making the difference between therapeutic plasma levels and subtherapeutic dosing. The compound's lipophilicity means it requires precise placement in adipose tissue, not muscle, to achieve the extended release profile that makes once-daily dosing effective.

Key takeaways

To inject tesofensine subq correctly, pinch subcutaneous fat, insert the needle at 45 degrees into adipose tissue 5–7mm deep, inject over 10–15 seconds, and rotate sites every 4–8 days to prevent lipohypertrophy.
Reconstituted tesofensine stored at 2–8°C remains stable for 28 days. Any temperature excursion above 8°C for more than 4 hours begins irreversible protein denaturation.
Subcutaneous injection into adipose tissue produces gradual absorption over 18–24 hours, maintaining steady-state plasma levels. Intramuscular injection accelerates absorption and shortens half-life by 40–60%.
The abdominal region offers the most consistent subcutaneous fat depth (15–25mm average) and fastest absorption kinetics. Outer thigh and deltoid are acceptable secondary sites with proper pinch technique.
Insulin syringes (27–30 gauge) minimise tissue trauma and injection-site reactions compared to larger-gauge needles. 0.5ml barrel size provides adequate volume for typical tesofensine doses of 0.1–0.3ml.
Never inject within 5cm of the navel, surgical scars, or areas with visible veins. Reduced vascular perfusion at these sites delays absorption by 30–50% and creates unpredictable pharmacokinetics.

We've worked with researchers using tesofensine in metabolic studies for years. The gap between doing it right and doing it wrong isn't the injection itself. It's the preparation sequence most protocols gloss over.

How do you inject tesofensine subq correctly?

To inject tesofensine subq, pinch a fold of subcutaneous fat at the injection site, insert a 27–30 gauge insulin syringe at a 45-degree angle into adipose tissue (5–7mm depth), inject slowly over 10–15 seconds, then withdraw and apply light pressure without rubbing. Proper site rotation. Abdominal quadrants, outer thigh, deltoid. Prevents lipohypertrophy and maintains consistent absorption across doses.

The distinction that matters: subcutaneous placement targets the layer between skin and muscle where vascular perfusion is slow enough to create sustained release. Intramuscular injection accelerates absorption, shortens half-life, and increases plasma concentration variability. Exactly what you don't want with a compound designed for steady-state norepinephrine and dopamine reuptake inhibition. This article covers how to inject tesofensine subq using proper reconstitution technique, site selection protocol, and injection angle that ensures adipose tissue placement every time.

Step 1: Reconstitute Lyophilised Tesofensine with Sterile Bacteriostatic Water

Lyophilised tesofensine arrives as a white powder in a sterile vial under vacuum seal. Reconstitution converts this into an injectable solution. But the sequence matters more than most protocols acknowledge. Use bacteriostatic water (0.9% benzyl alcohol), never sterile saline, because repeated needle punctures introduce contamination risk that benzyl alcohol suppresses for up to 28 days. Room temperature water (20–25°C) dissolves tesofensine faster than refrigerated water without compromising stability.

Withdraw the target volume of bacteriostatic water. Typically 2–3ml for a 5mg vial, giving you 2.5mg/ml or 1.67mg/ml concentration. Inject the water slowly down the inside wall of the vial, never directly onto the peptide powder. Direct impact causes foaming and protein denaturation. Let the vial sit undisturbed for 60–90 seconds. The powder will dissolve without agitation. Swirling is acceptable if dissolution is incomplete after two minutes, but never shake the vial. Shaking introduces microbubbles that denature the peptide structure irreversibly.

Store reconstituted tesofensine at 2–8°C (standard refrigerator temperature) and use within 28 days. Any temperature excursion above 8°C for more than 4 hours begins protein degradation that potency testing at home can't detect. Each 0.1ml drawn from a 2ml reconstituted vial at 2.5mg/ml concentration delivers 0.25mg tesofensine. Verify your math before drawing the first dose. We've seen researchers calculate backwards from total vial volume instead of concentration per ml, resulting in 3–4× overdosing. Concentration determines dose volume, not vial size.

Step 2: Prepare Injection Site and Sterilise the Target Zone

Subcutaneous fat depth varies by site. Abdominal tissue averages 15–25mm in most adults, outer thigh 10–18mm, deltoid 8–12mm. Select a site with sufficient adipose tissue that you can pinch a fold without pulling taut skin over muscle. The 'pinch test' is non-negotiable: if you can't gather 10mm of tissue between thumb and forefinger, the site lacks adequate subcutaneous depth and you risk intramuscular injection.

Rotate injection sites systematically to prevent lipohypertrophy (localised fat buildup) and lipoatrophy (fat loss). Both conditions impair absorption and create unpredictable pharmacokinetics. Divide the abdomen into four quadrants (left upper, left lower, right upper, right lower) and rotate through them on a 4–8 day cycle. Never inject within 5cm of the navel or any surgical scar. Scar tissue has reduced vascular perfusion that delays absorption by 30–50%.

Cleanse the site with 70% isopropyl alcohol using a circular motion from centre outward, covering a 5cm diameter area. Let the alcohol dry completely. Injecting through wet alcohol introduces it subcutaneously, causing stinging and tissue irritation. Drying takes 30–45 seconds. Don't blow on it, don't fan it, don't touch it. Just wait. Our team has learned this the hard way: every shortcut in the prep sequence shows up as injection-site reactions researchers incorrectly attribute to the peptide itself.

Step 3: Draw Tesofensine Dose Using Proper Syringe Technique to Avoid Contamination

Use a new insulin syringe (27–30 gauge, 0.5ml or 1ml barrel) for every injection. Never reuse syringes even for the same compound. Remove the vial cap and wipe the rubber stopper with a fresh alcohol prep pad. Let it dry 15 seconds. Draw air into the syringe equal to your target dose volume. This prevents vacuum formation inside the vial that makes subsequent draws progressively harder.

Insert the needle through the rubber stopper at a 90-degree angle, inject the air into the vial (not into the liquid. Aim for the headspace above the solution), then invert the vial so the needle tip is submerged. Draw slightly more than your target volume. If you need 0.2ml, draw 0.25ml. Hold the syringe at eye level, tap the barrel to consolidate air bubbles at the top, then push the plunger slowly to expel air and excess solution back into the vial until you reach exactly 0.2ml.

Double-check the dose volume before withdrawing the needle. The most common error we see in research settings isn't contamination. It's drawing 0.15ml when the protocol specifies 0.25ml because the researcher didn't account for dead space in the needle hub. Insulin syringes are calibrated to the plunger tip, but 0.03–0.05ml remains in the hub and needle after you stop pushing. For peptides where 0.1ml represents 0.25mg of active compound, a 0.05ml error is a 20% underdose.

Tesofensine Injection: Technique Comparison

Method	Needle Angle	Tissue Target	Absorption Rate	Risk of IM Injection	Professional Assessment
Subcutaneous (Standard)	45°	Adipose tissue 5–7mm depth	Gradual over 18–24 hours	Low if proper pinch technique used	RECOMMENDED. Ensures steady-state plasma levels matching clinical protocols
Subcutaneous (90° Perpendicular)	90°	Adipose tissue 8–12mm depth	Gradual over 18–24 hours	Moderate. Requires thick adipose layer	Acceptable for abdominal sites with >20mm fat; avoid in lean individuals or deltoid region
Intramuscular (Incorrect)	90°	Muscle tissue 15–25mm depth	Rapid over 4–8 hours	Guaranteed	AVOID. Accelerates absorption, shortens half-life, increases Cmax variability by 40–60%
Intradermal (Incorrect)	10–15°	Dermal layer 1–2mm depth	Minimal. Compound pools locally	None	AVOID. Causes injection-site reactions, poor systemic absorption, compound wastage

What If: Tesofensine Injection Scenarios

What If I Accidentally Inject Tesofensine Intramuscularly Instead of Subcutaneously?

You'll likely notice a sharper initial effect within 2–4 hours as the compound absorbs faster from muscle tissue. Followed by earlier offset than expected. Intramuscular injection isn't dangerous, but it defeats the extended-release design of subcutaneous protocols. Monitor for any unusual side effects (elevated heart rate, jitteriness, insomnia) that might indicate higher peak plasma concentration. Don't attempt to 'correct' it with an additional dose. Just resume proper subcutaneous technique at your next scheduled injection. The pharmacokinetic impact resolves within 24 hours.

What If the Injection Site Bleeds After I Withdraw the Needle?

Minor bleeding (a droplet or small streak) means you nicked a capillary. Completely normal and harmless. Apply light pressure with a clean gauze pad or alcohol wipe for 30–60 seconds. Don't rub or massage the site, as this can push the injected solution out of the subcutaneous space and into surrounding tissue. If bleeding continues beyond 2 minutes or forms a raised hematoma, you likely hit a larger vessel. Apply an ice pack for 10 minutes and avoid that exact spot for the next 7–10 days while it heals.

What If I Feel a Hard Lump at the Injection Site Hours After Injecting?

A firm subcutaneous nodule 4–12 hours post-injection usually indicates the solution pooled in one spot instead of dispersing through adipose tissue. Either because you injected too quickly (under 5 seconds) or the site has developing lipohypertrophy from repeated use. The lump will resolve on its own within 24–48 hours as the compound absorbs. Rotate to a different site for your next injection and slow your injection speed to 10–15 seconds. If lumps persist across multiple sites, consider switching to a lower concentration (dilute further with bacteriostatic water) to increase injection volume and improve dispersion.

What If the Reconstituted Solution Looks Cloudy or Has Floating Particles?

Discard the vial immediately. Cloudiness or visible particulates indicate bacterial contamination, protein aggregation, or incomplete dissolution. Properly reconstituted tesofensine is clear to slightly opalescent with no visible debris. Never inject a solution that looks abnormal. Contamination risks from multi-dose vials increase after 14 days even with bacteriostatic water, which is why 28-day stability is a maximum limit, not a target. If you're consistently seeing cloudiness within the first week, check your reconstitution technique. You may be injecting water directly onto the powder instead of down the vial wall, causing foaming and aggregation.

The Clinical Truth About Tesofensine Injection Technique

Here's the honest answer: most people who struggle with tesofensine protocols aren't failing because they can't handle the injection. They're failing because they're treating it like any other peptide. Tesofensine is lipophilic, meaning it has strong affinity for adipose tissue and relies on that environment for proper absorption kinetics. Inject it into muscle, and you get a pharmacokinetic profile that doesn't match any published dosing research. Inject it intradermally, and it pools at the injection site with minimal systemic absorption.

The other reality researchers need to hear: site rotation isn't optional. Injecting the same 2cm spot every day creates lipohypertrophy within 4–6 weeks. Localised fat accumulation that looks like a firm lump under the skin and reduces absorption by 30–40%. Once it develops, it takes 8–12 weeks to resolve even with complete site avoidance. We've worked with research teams who attributed poor tesofensine response to peptide quality when the actual problem was injection-site damage from inadequate rotation.

The technique itself. 45-degree angle, slow injection, proper pinch. Is straightforward. What separates successful protocols from failed ones is the discipline to execute every step the same way every time. Subcutaneous injection is a procedural skill, not an art form. Follow the sequence, rotate the sites, and the compound does what it's designed to do.

Proper injection technique is only half of a complete research peptide protocol. Our FAT Loss Stack combines synergistic compounds designed for subcutaneous administration with full reconstitution and dosing guidance. If you're exploring tesofensine as part of metabolic research, understanding how complementary peptides interact can deepen your experimental framework and improve reproducibility across trials.

Subcutaneous injection mastery for tesofensine isn't about perfect needle placement. It's about eliminating every variable that introduces dose-to-dose inconsistency. Get the reconstitution right, rotate your sites methodically, and inject at the correct angle into adipose tissue. That's the entire protocol. Everything else is just noise.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on Tesofensine indexed in PubMed, listed for research context. Real Peptides supplies Tesofensine for laboratory research use only.

Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PloS one, 2024. PMID 38656972. doi:10.1371/journal.pone.0300544
Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring, Md.), 2013. PMID 23784901. doi:10.1002/oby.20122
Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacology, biochemistry, and behavior, 2013. PMID 23932919. doi:10.1016/j.pbb.2013.07.018
The effect of tesofensine on appetite sensations. Obesity (Silver Spring, Md.), 2012. PMID 21720440. doi:10.1038/oby.2011.197
Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012. PMID 21889317. doi:10.1016/j.euroneuro.2011.07.015
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clinical pharmacology and therapeutics, 2010. PMID 20520602. doi:10.1038/clpt.2010.67
Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. PMID 20200509. doi:10.1038/npp.2010.16
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. European journal of pharmacology, 2010. PMID 20385125. doi:10.1016/j.ejphar.2010.03.026

Questions

To inject tesofensine subq without reactions, ensure the alcohol prep pad is completely dry (30–45 seconds) before inserting the needle, inject slowly over 10–15 seconds to allow tissue dispersion, and rotate sites every 4–8 days to prevent lipohypertrophy. Most injection-site reactions — redness, swelling, itching — result from injecting through wet alcohol, injecting too quickly (under 5 seconds), or reusing the same 2cm area repeatedly. If reactions persist despite proper technique, consider diluting the reconstituted solution further to increase injection volume and improve dispersion through adipose tissue.

No — injecting tesofensine subq in the same site daily causes lipohypertrophy (localised fat accumulation) within 4–6 weeks, which reduces absorption by 30–40% and creates firm subcutaneous nodules that take 8–12 weeks to resolve. Rotate through at least four distinct sites (abdominal quadrants, outer thigh, deltoid) on a systematic schedule, never returning to the same 2cm area within 7 days. Site rotation isn't a suggestion — it's a hard requirement for maintaining consistent pharmacokinetics across repeated doses.

Use a 27–30 gauge insulin syringe with a 0.5ml or 1ml barrel to inject tesofensine subq — this needle length (typically 6–8mm) and gauge minimise tissue trauma while ensuring proper adipose tissue penetration at a 45-degree angle. Larger-gauge needles (25G or thicker) increase injection-site pain and bleeding risk without improving delivery. Shorter needles (4–5mm) may not reach subcutaneous fat in individuals with thicker skin, resulting in intradermal injection and poor absorption. Standard insulin syringes are purpose-built for subcutaneous peptide administration and are the correct tool for this application.

Subcutaneously injected tesofensine absorbs gradually over 18–24 hours, reaching peak plasma concentration (Tmax) approximately 4–6 hours post-injection and maintaining therapeutic levels through the dosing interval. This extended absorption profile is the reason tesofensine is dosed once daily rather than multiple times per day — the subcutaneous depot in adipose tissue acts as a slow-release reservoir. Intramuscular injection accelerates absorption to 4–8 hours total, shortening the half-life and increasing Cmax variability by 40–60%, which is why proper subcutaneous technique matters for protocol consistency.

A 45-degree angle ensures needle placement in the subcutaneous fat layer (5–7mm depth) for individuals with typical adipose tissue thickness, while a 90-degree angle penetrates 8–12mm and risks intramuscular injection in lean individuals or sites with thinner fat deposits like the deltoid. The 45-degree technique is safer and more forgiving — even if you misjudge tissue depth slightly, you remain in the subcutaneous space. A 90-degree injection is acceptable only in the abdominal region where subcutaneous fat exceeds 20mm, but it offers no absorption advantage and increases the risk of incorrect tissue targeting.

Injecting a small air bubble (0.01–0.05ml) subcutaneously is harmless — the air absorbs into surrounding tissue within minutes without causing embolism or adverse effects. Subcutaneous air injections do not enter the bloodstream the way intravenous air can. However, large air volumes (0.2ml+) can cause temporary discomfort, a visible raised area under the skin, and reduced effective dose because the air displaces the peptide solution. Always expel air bubbles from the syringe before injection by tapping the barrel and pushing the plunger until a small droplet of solution appears at the needle tip.

Divide your available injection sites into at least four zones — left upper abdomen, left lower abdomen, right upper abdomen, right lower abdomen — and rotate through them sequentially, injecting a different zone each day. Add outer thigh (left and right) and deltoid (left and right) as secondary sites if you want an eight-site rotation for more spacing between repeat uses. Never inject within 5cm of a previous injection site until at least 7 days have passed. Mark injection dates on a body diagram or use a rotation app if you're injecting daily long-term — visual tracking prevents accidental site reuse and lipohypertrophy development.

No — do not massage the injection site after injecting tesofensine subq. Massaging pushes the injected solution out of the subcutaneous depot and into surrounding tissue, accelerating absorption and potentially causing the compound to enter capillaries prematurely, which alters pharmacokinetics. Apply light pressure with a gauze pad for 30–60 seconds if there's minor bleeding, but avoid rubbing or kneading the area. Let the solution disperse naturally through adipose tissue — this is how subcutaneous injections are designed to work.

No — discard any reconstituted tesofensine that has been stored above 8°C for more than 4 hours. Peptides undergo irreversible thermal denaturation at room temperature (20–25°C), and while the solution may look clear and normal, potency degrades by 15–30% within 12 hours and 50%+ within 24 hours. Refrigeration at 2–8°C is non-negotiable for maintaining peptide stability post-reconstitution. If you accidentally left the vial out overnight, don't inject it — peptide degradation isn't visible to the eye, and you'll be administering a subtherapeutic dose without realising it.

Stinging during or immediately after injection usually indicates you injected through wet alcohol (didn't allow the prep pad to dry fully), the solution's pH is slightly acidic relative to tissue pH, or you injected too quickly causing rapid tissue distension. Let alcohol dry completely for 30–45 seconds before inserting the needle, and inject over 10–15 seconds rather than pushing the plunger in 2–3 seconds. If stinging persists despite proper technique, the bacteriostatic water's benzyl alcohol content (0.9%) may be irritating — try switching to a different brand of bacteriostatic water or reduce injection speed further to 20 seconds.

Metabolic research protocols studying tesofensine's effects on norepinephrine and dopamine reuptake inhibition require precise subcutaneous administration because absorption kinetics directly affect plasma concentration curves and half-life measurements — intramuscular injection would invalidate pharmacokinetic data by shortening Tmax and increasing Cmax variability. Body composition studies, energy expenditure trials, and appetite regulation experiments also depend on consistent dosing through proper subq technique to ensure each subject receives equivalent systemic exposure. Any research comparing tesofensine to other compounds (such as semaglutide, BPC-157, or metabolic peptides) must standardise injection methodology across all agents to isolate the compound's effect from delivery-method variables.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA